Karyopharm to Report Fourth Quarter and Full Year 2015 Financial Results on March 14, 2016
Mar 07, 2016 12:00 pm UTC| Business
NEWTON, Mass., March 07, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2015 financial results and provide a...
PRA Group to Present at the Raymond James 37th Annual Institutional Investors Conference
Mar 07, 2016 12:00 pm UTC| Business
NORFOLK, Va., March 07, 2016 -- PRA Group (Nasdaq:PRAA), a global leader in acquiring and collecting nonperforming loans, will present to investors attending the Raymond James 37th Annual Institutional Investors...
Zynerba Pharmaceuticals to Present at 28th Annual ROTH Conference
Mar 07, 2016 12:00 pm UTC| Business
DEVON, Pa., March 07, 2016 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that...
Mar 07, 2016 11:45 am UTC| Business
WATERLOO, Ontario, March 07, 2016 -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Rotech Healthcare has selected Descartes’...
Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference
Mar 07, 2016 11:45 am UTC| Business
RESEARCH TRIANGLE PARK, N.C., March 07, 2016 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that results from a preclinical study of its broad spectrum antiviral BCX4430 in immune-deficient mice...
Special Olympics Canada 2016 Winter Games Come to a Close
Mar 07, 2016 11:35 am UTC| Business
CORNER BROOK, NL, March 7, 2016 -- The Special Olympics Canada 2016 Winter Games have officially wrapped up after a week of fierce competition and incredible displays of sportsmanship. The Games, hosted in Corner Brook,...
Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397
Mar 07, 2016 11:30 am UTC| Business
SAN DIEGO, March 07, 2016 -- Vical Incorporated (Nasdaq:VICL) today announced the initiation of a Phase 1 clinical trial of the company’s novel antifungal, VL-2397. The randomized, double-blind trial will evaluate...